About two-thirds of patients who take popular weight loss drugs end their regimen within a year, according to a Prime Therapeutics study released July 11.
Payer
Cigna has received final approval from a federal court in Connecticut on a $300,000 class settlement with plaintiffs who alleged the company violated its fiduciary duties under ERISA by overcharging for laboratory services from certain providers.
The Cigna Group's network of behavioral health providers grew by more than 30 percent in 2022, according to the company's 2022 Environmental, Social, and Governance Report.
Total risk adjustment payments in individual and small group insurance plans increased in 2022, according to new data from CMS.
Cigna is adding three Humira biosimilars to its formulary beginning Sept. 1.
Advertisement
GLP-1 drugs like Ozempic and Wegovy are contributing to increasing premium rates in Michigan's small-group and individual insurance markets, the Detroit Free-Press reported July 10.
BlueCross BlueShield of Tennessee reported $21.8 million in net income for 2022, down from $521.1 million in 2021.
Leqembi, the newly-approved drug that can slow the progression of Alzhemier's disease, will cost Medicare billions each year, according to an analysis from KFF.
A federal judge in Connecticut has denied a class-action bid against Cigna for allegedly overcharging members for medical equipment and violating its fiduciary duties under the Employee Retirement Income Security Act.
A New York judge has temporarily blocked New York City's plan to switch 250,000 retired city employees from traditional Medicare to an Aetna Medicare Advantage plan.